10-Q: Silexion Therapeutics Reports Q1 2025 Results, Cites Going Concern Uncertainty Amidst Ongoing Development

Silexion Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Summary

• Silexion Therapeutics Corp reported its financial results for the quarter ended March 31, 2025.
• The company is a clinical-stage, oncology-focused biotechnology company developing treatments for cancers driven by the KRAS oncogene.
• Their lead product candidate, SIL204, is intended as a first-line treatment for locally advanced pancreatic cancer patients.
• The company incurred a net loss of $1.7 million for the three months ended March 31, 2025, compared to a net loss of $1.4 million for the same period in 2024.
• Research and development expenses decreased to $0.6 million from $1.0 million year-over-year, while general and administrative expenses increased to $1.1 million from $0.3 million.
• As of March 31, 2025, the company had cash and cash equivalents of $6.2 million.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional funding.
• The company is evaluating various financing alternatives, including the ELOC Agreement.
• The company effected a 1-for-9 reverse share split on November 27, 2024.
• The company has raised capital through public offerings and warrant exercises, including approximately $5.0 million from a public offering in January 2025 and $3.3 million from an induced warrant exercise.
• The company has received $5.8 million in royalty-bearing grants from the Israeli Innovation Authority (IIA) and is committed to paying royalties at a rate of 3.0% to 5.0% of sales of products developed using these grants.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's financial losses, going concern uncertainty, and reliance on dilutive financing methods. While there are some positive aspects, such as the potential of its lead product candidate, the overall financial situation is concerning.

Positives

• The company successfully raised capital through a public offering and an induced warrant exercise in January 2025, generating approximately $8.3 million in gross proceeds.
• Research and development expenses decreased year-over-year, potentially indicating improved efficiency or a shift in focus.
• The company has access to an equity line of credit (ELOC) for up to $15.0 million, providing a potential source of additional funding.
• The company's lead product candidate, SIL204, is in development as a first-line treatment for locally advanced pancreatic cancer, addressing a significant unmet medical need.

Negatives

• The company reported a net loss of $1.7 million for Q1 2025, indicating ongoing financial challenges.
• Management has expressed substantial doubt about the company's ability to continue as a going concern without additional funding, raising concerns about its long-term viability.
• General and administrative expenses increased significantly, potentially reflecting increased costs associated with operating as a public company.
• The company has an accumulated deficit of $45 million, highlighting its history of operating losses.
• The company is committed to paying royalties to the IIA on sales of products developed using IIA grants, which could reduce future profitability.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding, which may not be available on acceptable terms or at all.
• The company's reliance on public offerings and warrant exercises for funding could lead to significant dilution for existing shareholders.
• The company's product candidates may not receive regulatory approval or achieve commercial success.
• The company faces competition from other companies developing treatments for pancreatic cancer.
• The company's operations could be adversely affected by geopolitical events, such as the conflict between Israel and Hamas.
• The company is subject to the risks associated with operating as a public company, including increased compliance costs and regulatory scrutiny.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future and will need to obtain substantial additional funding.

Management Comments

• Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months from the date these financial statements are issued.
• Management is in the process of evaluating various financing alternatives, including financing via the ELOC Agreement, as the Company will need to finance future research and development activities, general and administrative expenses and working capital through fund raising.

Industry Context

Silexion is operating in the competitive biotechnology industry, specifically targeting pancreatic cancer, which has a high unmet medical need. Companies like BioNTech and Moderna are also exploring RNA-based therapies for cancer, indicating a broader industry trend towards this approach. Silexion's focus on KRAS silencing differentiates it from some competitors, but it also faces the challenges inherent in developing novel therapies.

Comparison to Industry Standards

• Comparing Silexion's financial metrics to industry benchmarks is challenging due to its development-stage nature.
• Companies like Arrowhead Pharmaceuticals and Alnylam Pharmaceuticals, which are further along in developing RNAi therapeutics, have significantly higher market capitalizations and R&D spending.
• Silexion's cash runway of approximately 9 months is shorter than many of its peers, highlighting the urgency of securing additional funding.
• The company's reliance on public offerings and warrant exercises for funding is a common strategy for small-cap biotech companies, but it can lead to significant dilution.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and the potential loss of investment if the company is unable to continue as a going concern.
• Employees face uncertainty about their job security due to the company's financial challenges.
• Customers (patients) may benefit from the development of new treatments for pancreatic cancer, but the company's financial instability could delay or halt development.
• Suppliers and creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company needs to secure additional funding to continue its operations and development programs.
• The company plans to continue developing SIL204 and conduct pre-clinical and clinical trials.
• The company may apply for Orphan Drug Designation in the U.S. and EU for SIL204.
• The company will seek marketing approvals for SIL204 in various territories.
• The company will maintain, expand, and protect its intellectual property portfolio.

Key Dates

Keywords

Silexion Therapeutics, financial results, going concern, SIL204, KRAS, pancreatic cancer, RNA interference, public offering, warrant exercise, ELOC, Israeli Innovation Authority